Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8414395 | European Journal of Pharmaceutics and Biopharmaceutics | 2013 | 8 Pages |
Abstract
In this work, the neuroregenerative potentials of microencapsulated VEGF, GDNF and their combination on a severely lesioned rat model were compared with the aim of developing a new strategy to treat advanced stages of Parkinson's disease. Both neurotrophic factors were separately encapsulated into polymeric microspheres (MSs) to obtain a continuous drug release over time. The regenerative effects of these growth factors were evaluated using a rotation behaviour test and quantified by the number of surviving THÂ +Â cells. The biological activities of encapsulated vascular endothelial growth factor (VEGF) and glial cell line-derived neurotrophic factor (GDNF) were investigated in HUVEC and PC12 cells, respectively. The treatment of 6-OHDA-lesioned rats with GDNF microspheres and with both VEGF and GDNF microspheres resulted in improved results in the rotation behaviour test. Both groups also showed higher levels of neuroregeneration/neuroreparation in the substantia nigra than the control group did. These results were confirmed by the pronounced THÂ +Â neuron recovery in the group receiving VEGFÂ +Â GDNF-MS, demonstrating regenerative effects.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Enara Herrán, José Ángel Ruiz-Ortega, Asier Aristieta, Manoli Igartua, Catalina Requejo, José Vicente Lafuente, Luisa Ugedo, José Luis Pedraz, Rosa MarÃa Hernández,